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ABSTRACT
Background: Melasma is an acquired hyperpigmentary disorder characterized 
by dark patches or macules located on the cheeks, forehead, upper lip, chin, and neck. 
Treatment of melasma involves the use of topical hypopigmenting agents such as 
hydroquinone, tretinoin, and azelaic acid and its derivatives.
Objective: The purpose of this study was to assess the efficacy of a formulation 
containing a combination of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium 
azeloyl diglycinate/niacinamide compared with an emulsion-based control in the treat-
ment of melasma in Thai adults.
Methods: In this single-center, randomized, double-blind, controlled study, 
Thai patients with mild to moderate facial melasma (relative melanin value [RMV] in 
range of 20–120) were randomized for the application of either the test or the emulsion-
based (control) product in the morning and before bedtime for 8 weeks. The supplemental 
sunscreen product with sun protection factor 30 was distributed to all patients. Sub-
jects were assessed for the intensity of their hyperpigmented skin area by measuring 
the difference in the absolute melanin value between hyperpigmented skin and nor-
mal skin (RMV). This parameter was used as a primary outcome of this study. Addi-
tionally, the severity of melasma was determined visually using the Melasma Area and 
Severity Index (MASI) scored independently by 3 investigators. The assessments of 
melasma intensity and other skin properties were performed before administration 
(week 0) and every 2 weeks thereafter for up to 8 weeks. Other skin properties, including 
moisture content, pH, and redness (erythema value), were measured. Adverse events 
(AEs), including erythema, scaling, and edema, were also assessed by a dermatologist 
using the visual grading scale of Frosch and Kligman and COLIPA.
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Results: The resulting primary intent-to-treat (ITT) population included 33 pa-
tients in the test group and 34 patients in the control group. Sixty patients completed 
all 8 weeks of the study (on-treatment [OT] population): 91% (30) of the 33 patients 
in the test group, and 88% (30) of the 34 patients in the control group. Between-
group differences in mean RMV were statistically significant at week 6 in both the 
primary ITT (P = 0.005) and OT (P = 0.006) populations. The significant differences 
in mean MASI scores between the test and the control groups were initially observed 
at weeks 4 (P = 0.005) and 8 (P = 0.027) in the OT and primary ITT populations, re-
spectively. Other parameters, including skin pH, erythema, and moisture content did 
not significantly change from baseline at any time point of study. The incidence of AEs 
was not different between the test (4/33 [12%]) and control (5/34 [15%]) groups.
Conclusions: The significant differences in RMVs between the test and con-
trol groups were observed after 6 weeks of treatment, both in the primary ITT and 
OT populations. The incidence of patients with AEs was not significantly different 
between the test and control groups. (Curr Ther Res Clin Exp. 2010;71:345–359) 
© 2010 Elsevier HS Journals, Inc.
Key words: trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl 
diglycinate/niacinamide, melasma, Thai adults.
INTRODUCTION
Melasma is an acquired hyperpigmentary disorder characterized by dark patches or 
macules located on the cheeks, forehead, upper lip, chin, and neck.1,2 This disorder is 
predominantly found in females, accounting for ~90% of all cases. It appears in all racial 
types, but occurs more frequently in persons with darker complexions (Fitzpatrick’s 
skin type IV through VI).3,4 The prevalence of melasma in Latino females varies from 
1.5% to 33.3%.5 Besides racial types, sunlight exposure is essential to melasma de-
velopment. Melasma is considered to be a cosmetic problem as there are no pain or 
other associated symptoms.5,6
Treatment of melasma involves the use of topical hypopigmenting agents such as 
hydroquinone, tretinoin, and azelaic acid and its derivatives.7,8 A combination of hypo- 
pigmenting agents with different mechanisms of action has been found to be an effica-
cious treatment due to improved clinical efficacy and reduced duration of therapy as 
well as risk of adverse effects.7,9 In this study, the combination of trans-4-(aminomethyl) 
cyclohexanecarboxylic acid (tranexamic acid [TXA])/potassium azeloyl diglycinate/
niacinamide* was assessed for its clinical efficacy in improving hyperpigmented lesions. 
TXA is a synthetic derivative of lysine. It has been found that topical application of 
TXA can prevent ultraviolet radiation-induced hyperpigmentation of the dorsal skin 
of Weiser-Maples guinea pigs.10 Its possible action is to block the release of prosta-
glandin, an activator of tyrosinase.11 However, clinical reports on the topical use of 
TXA for treatment of melasma are currently limited. Potassium azeloyl diglycinate† 
*Trademark: PEM-C (Pazana Laboratory Asia Co., Ltd, Bangkok, Thailand).
†  Trademark: Azeloglicina® (Beijing Brilliance Biochemical Co., Ltd., Beijing, China).
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(PAD) is a chemical modification of azelaic acid. Its mechanism of action has been 
found to be competitive inhibition of tyrosinase.12,13 This molecule has been found to 
be better tolerated than azelaic acid.12 The results of an efficacy study suggest that it 
improves skin brightness and reduces pigmentation.14 Niacinamide, also known as 
nicotinamide, is the pyridine-3-carboxylic acid amide form of niacin, a component of 
vitamin B complex. It has been reported to inhibit melanosome transfer to keratino-
cytes in an in vitro study.15 The results from a study in Japanese women indicated that 
5% niacinamide significantly decreased hyperpigmentation and increased skin light-
ness compared with the vehicle alone after 4 weeks of use. According to the different 
actions on hypopigmentation of these compounds, it was expected that the synergistic 
effects of the combination would occur, resulting in an improvement in hyperpig-
mented lesions with no serious adverse events (AEs).
PATIENTS AND METHODS
Study Design
The design of this study was a randomized, double-blind and emulsion-based, 
controlled trial. The study was conducted at the Cosmetics and Natural Products 
Research Center, Naresuan University, Phitsanulok, Thailand, from April through 
July 2008, in patients with facial melasma. The study protocol was approved by an 
institutional review board of Naresuan University (Approval Code: 51 02 04 0010; 
Approval Date: February 26, 2008). A simple randomization scheme was used for al-
location of eligible patients to the test or control groups. Random code (A or B) was 
prepared by independent staff by using a random table, and was concealed up to the 
time of allocation in sealed envelopes labeled with a unique patient number. These 
envelopes were opened sequentially after consent was obtained to enroll an eligible 
patient (at week 0 or before treatment). The product labeled with code A or B was 
then distributed to the patients by an independent staff member. Code allocation was 
concealed from all investigators, the dermatologist, and researchers until after data 
analysis was complete.
Study Population
In this study, the recruitment of patients was performed through advertising. Thai 
male and female patients with mild-to-moderate epidermal melasma, ranging from 
mild and discontinuous to moderate and homogeneous, as determined by a derma-
tologist were firstly recruited to the study. Patients were randomized for the applica-
tion of the test product containing the combination of trans-4-(aminomethyl) cyclo-
hexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide. The improvement 
in hyperpigmentation after application was objectively evaluated by the relative 
melanin value (RMV) measured with a pigmentation/erythema measuring device 
(Mexameter MX 18, Courage and Khazaka Electronic GmbH, Köln, Germany). This 
value indicates the intensity of pigmentation relative to the surrounding normal 
skin.16 Additionally, clinical evaluation by investigators through the Melasma Area 
and Severity Index (MASI) was performed. To be eligible for the study, patients had 
to have RMVs in the range of 20 to 120.16,17 Subjects were excluded if they were a 
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smoker or alcoholic, a drug abuser, pregnant, nursing or planning to become preg-
nant, or had used topical steroids, hormones, antibiotics, NSAIDs, antihistamines, or 
medicated cosmetics containing alpha hydroxy acids, retinoids, azelaic acid, kojic ac-
id, hydroquinone, chemical peels and/or other substances which might induce hypo- 
pigmentation on the face within 4 weeks of the start of the study; used systemic ster- 
oids, hormones, antibiotics, NSAIDs, antihistamines, or isotretinoin within 4 weeks 
of the start of the study; had a known allergy or sensitivity to any components con-
tained in the product; or had any disease that might interfere with the evaluation of 
hyperpigmentation. All analyses were performed on the primary intent-to-treat (ITT) 
and on-treatment (OT) populations. The primary ITT population included all 
patients who had baseline assessment and received the product after randomization; 
missing data were handled by assigning the value recorded at the last patient visit. 
The OT population included those patients in the study who had an observational 
value and measurement for skin properties at that particular time point in the 
study.
Study Protocol
At week 0 of the study, patients arrived at the study room at 8:00 am. They then 
were asked to wash their face with clean water, pat the face dry with a towel, and wait 
for 30 minutes before proceeding to the next step of measuring the skin properties. 
Absolute melanin values at the hyperpigmented area and the normal area of each 
melasma location (forehead, right and left malar, and chin) were measured and RMV 
was determined. A mean of RMVs from 4 areas was used to indicate the intensity 
of pigmentation disorder in each patient. Other skin conditions including moisture 
content, pH, and redness (erythema value) were measured by using a skin hydration 
measurement device (Corneometer CM 825, Courage and Khazaka Electronic GmbH), 
pH measurement device (Skin-pH-Meter pH 900, Courage and Khazaka Electronic 
GmbH), and the previously mentioned pigmentation/erythema measurement device, 
respectively. The measurement room had a controlled temperature of 27±2°C and 
relative humidity of 55%±5%. Four measurements were taken of each facial area 
(forehead, right and left malar, and chin) that was the target site of product applica-
tion. The mean of these 4 values indicated the skin moisture, pH, or redness of each 
patient. After completing baseline measurements, color photographs of patients were 
taken (EOS 400D with an EFS 18–55 mm lens, Canon Inc., Tokyo, Japan). Melasma 
severity of each patient was then scored using the MASI.2,18,19 In the MASI system, 
the face is divided into 4 areas: forehead, right malar, left malar, and chin that correspond, 
respectively, to 30%, 30%, 30%, and 10% of total face area. The melasma in each 
of these areas was graded on 3 variables: percentage of total area involved on a scale 
from 0 (no involvement) to 6 (90%–100% involvement); darkness on a scale from 0 
(absent) to 4 (severe); and homogeneity on a scale of 0 (minimal) to 4 (maximum). The 
MASI was then calculated with the following equation: 
MASI = 0.3 (DF + HF) AF + 0.3 (DMR + HMR) AMR + 
0.3 (DML + HML) AML + 0.1 (DC + HC) AC, 
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where D was darkness, F was forehead, H was homogeneity, A was area, MR was right 
malar, ML was left malar, C was chin, and the values 0.3, 0.3, 0.3, and 0.1 were the 
respective percentages of total facial area.
The MASI grading of each patient was performed by 2 investigators (P.T. and J.V.). 
The investigators performed this grading independently and blind of each other’s 
grading. Additionally, the MASI grading was assessed from photographs by one in-
vestigator (K.P.) who was blind to the MASI scores of the other investigators and to 
the patient’s status whether it was before or after treatment. The mean from 3 values 
was used to indicate the melasma intensity of each patient. In this study, while assess-
ing the photographs, details of the patient’s face (eg, eyes, mouth) were concealed so 
that only the lesions were evaluated.
The enrolled patients then received either the test or the emulsion-based product. 
A personal diary for recording application time and adverse symptoms was also dis-
tributed to each patient.
Subjects were scheduled for study visits every 2 weeks to determine skin properties, 
including melanin and MASI values. Photographs of the patients were taken at each 
visit. AEs, including erythema, scaling, and edema, were also assessed by the derma-
tologist (P.T.) using the visual grading scale of Frosch and Kligman and COLIPA.20–22 
The scale ranged from 0 to 4 as follows: erythema, 0 = no evidence of erythema, 0.5 = 
minimal or doubtful erythema, 1 = slight redness, spotty, and diffuse, 2 = moderate 
and uniform redness, 3 = intense redness, and 4 = fiery redness; scaling, 0 = no evi-
dence of scaling, 0.5 = dry without scaling or appears smooth and taut, 1 = fine or mild 
scaling, 2 = moderate scaling, and 3 = severe scaling with large flakes; and edema, 0 = 
absence of edema, and 1 = presence of edema. The same dermatologist assessed all 
enrolled patients.
Additionally, patients were interviewed by the same dermatologist if any AEs were 
apparent at each visit. Possible AEs were red skin, burning/stinging, itching, rash, 
papules, swelling, eczema, or blistering. The personal diaries are also examined for 
AEs recorded by the patients themselves.
Directions for Use of Products
Interventions of this study were 2 different products including the test (emulsion-
base with the combination 6.5% trans-4-[aminomethyl] cyclohexanecarboxylic acid/
potassium azeloyl diglycinate/niacinamide) and the control (emulsion-base alone). The 
emulsion-base consisted of polypropylene glycol-15 stearyl ether, isohexadecane, steareth-2, 
steareth-21, stearic acid, cetearyl alcohol, polyacrylamide, C13–14 isoparaffin, laureth-7, 
dimethicone, glycerine, phenoxyethanol, methylparaben, propylparaben, ethylparaben, 
butylparaben, isobutylparaben, sodium hyaluronate, and perfume. Both test and con-
trol products were prepared by Pazana Laboratory Asia Co., Ltd, and were similar in 
their physical characteristics and packaging.
Patients received written instructions and verbal explanations of the instructions. 
The assigned product was applied to melasma areas twice a day (at morning and at 
bedtime) after washing of the facial skin. The duration of application was 8 consecu-
tive weeks. Patients were also provided with supplemental sunscreen product with 
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sun protection factor (SPF) 30 (Pazana Laboratory Asia Co., Ltd). The sunscreen 
agents incorporated in the sunscreen product were 4.00% w/w titanium dioxide and 
2.32% w/w ethylhexyl methoxycinnamate. Other ingredients included butylene glycol 
cocoate, caprylic/capric triglycerides, isononyl isononanoate, dimethicone, cetyl dime-
thicone, candelilla/jojoba/rice bran polyglyceryl-3 ester (and) glyceryl stearate (and) 
cetearyl alcohol (and) sodium stearoyl lactylate, polysilicone-14, cetearyl alcohol, 
diglyceryl-2 diisostearate, glyceryl stearate SE, nicotinamide, magnesium aluminum 
silicate, shea butter, butyl methoxydibenzoylmethane, phenoxyethanol, ectoin, xanthan 
gum, tetrasodium EDTA, methylparaben, propylparaben, ethylparaben, butylparaben, 
isobutylparaben, and fragrance. Any moisturizer free from the agents specified in the 
exclusion criteria could be used after application of the test product or emulsion-base. 
Subjects were instructed not to take medication or apply topical medicine on the face 
during the study period. In addition, they were instructed not to apply any founda-
tion, powder, or make-up to the face on the morning of a scheduled study visit, and 
avoid or minimize sun exposure and sunlamps during the study periods. The supplied 
sunscreen was applied to the face whenever sun exposure was anticipated, and wearing 
protective clothing was advised.
Determination of Subject Compliance
Patients were asked to return the used product and the sunscreen product while 
receiving the new one at each visit. The returned product was weighed by an investi-
gator to monitor patient compliance.
Additionally, patients were interviewed by the dermatologist to determine if they 
were applying the product properly. The application time recorded in the personal diary 
was also examined.
Statistical Analysis
Descriptive statistics were used to report all results of this study in terms of mean 
(SD) and percentage (%). The mean differences of each of the skin parameters between 
treatments were analyzed using a 2-sample t test. P < 0.05 was considered statistically 
significant. Repeated-measures ANOVA was also used to compare mean RMV or 
MASI score at various time points during the administration of the product to the 
baseline value. The Bonferroni correction was performed to correct for multiple com-
parisons (P = 0.05/4 = 0.0125). Inter-rater reliability for MASI scored by an indi-
vidual investigator was measured using the intraclass correlation coefficient (ICC). 
The Pearson correlation coefficient was used to evaluate the relation between the 
MASI and RMV.
RESULTS
Subject Disposition and Baseline Characteristics
Flow of patients through the study is shown in the figure. One hundred and 
thirty-nine Thai patients were assessed for enrollment and 67 patients were enrolled and 
randomized. The resulting primary ITT population included 33 patients in the test 
group and 34 patients in the control group. Of the primary ITT population, 60 patients 
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completed all 8 weeks of the study: 30 of 33 patients (91%) in the test group and 30 
of 34 patients (88%) in the control group.
Table I shows the demographic and mean baseline characteristics of the popu- 
lation. The enrolled patients ranged in age from 27 to 54 years (mean [SD], 42.2 
[6.4] years) and were predominantly female (65 [97%]). The majority in both groups 
had melasma with RMVs in the range of 20 to 120 (test group, 79.1 [19.9] and con-
trol group, 75.3 [14.4]). There was not a statistically significant difference between 
groups in regard to age or any other demographic parameter. Patients in both groups 
were assessed by a dermatologist and reported as having no erythema, peeling, dry-
ness, burning/stinging, or itching during the entire 8 weeks of treatment. 
Initially screened for recruitment
(N = 139)
Met inclusion and exclusion criteria for enrollment,
signed informed-consent form, and randomized
(n = 67)
Measured baseline characteristics
Received the test product
(Primary ITT population, n = 33)
Received the emulsion-based
control product
(Primary ITT population, n = 34)
Withdrew (n = 3)
   Facial dermatitis (2)
   Loss to follow up (1)
Withdrew (n = 4)
   Facial dermatitis (3)
   Other (1)
Completed study
(OT population, n = 30)
Completed study
(OT population, n = 30)
Figure.  Subject disposition throughout the course of the study. ITT = intent-to-treat; OT = 
on-treatment.
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Efficacy
Mean (SD) values of the measured parameter in the test and emulsion-based groups 
the primary ITT and OT populations are shown in Table II. In the OT popula- 
tion, the significant differences in mean RMV between the test (mean [SD], 63.1 
[16.8] units) and the control (75.0 [15.5] units) groups were first observed at week 6 
(P = 0.006). Focusing on the within-group results for the test product, a statistically 
significant decrease in RMV from the baseline was initially observed at week 4 (F = 
13.92; P = 0.001). No significant within-group decreases from baseline in RMVs were 
noted at any visits in the control group. By the eighth week of treatment, a decrease in 
RMVs from baseline was observed in 25 test patients (83%) and 15 controls (50%).
Table I.  Demographic and baseline characteristics of patients enrolled in the study 
(N = 67).
Characteristic
Test Group 
(n = 33)
Control Group 
(n = 34) P*
Age, mean (SD), y 43.1 (6.3) 41.3 (6.4) 0.260
Sex, no. (%)
  Male 1 (3) 1 (3)
  Female 32 (97) 33 (97)
Race, no. (%)
  Asian (Fitzpatrick skin type IV) 33 (100) 34 (100)
Education, no. (%)
  Less than primary school 4 (12) 1 (3)
  Primary school 19 (58) 14 (41)
  High school 4 (12) 14 (41)
  Bachelor’s degree or equivalent 6 (18) 5 (15)
Occupation, no. (%)
  Government officer 2 (6) 1 (3)
  Contingent worker 9 (27) 19 (56)
  Agriculturalist 9 (27) 5 (15)
  Freelance/personal business 5 (15) 6 (18)
  Unemployed 8 (24) 3 (9)
Skin properties, mean (SD)
  Moisture content, AU† 59.6 (7.8) 58.8 (8.2) 0.695
  Skin pH 5.1 (0.5) 5.2 (0.5) 0.236
  Erythema value, AU 339.0 (59.8) 337.1 (58.1) 0.899
  RMV, AU 79.1 (19.9) 75.3 (14.4) 0.370
  MASI score 17.3 (5.4) 15.9 (6.6) 0.351
AU = arbitrary unit; RMV = relative melanin value; MASI = Melasma Area and Severity Index.
*2-Group t test with a 2-sided significance level of 0.05.
†  One unit represents a water content of stratum corneum of 0.02 mg/cm2.
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In the primary ITT population, based on the comparison between mean RMVs, sig-
nificant differences were found at week 6 (P = 0.005) of the visits comparing the test 
(63.0 [16.4] units) and control (74.0 [14.2] units) groups. For the within-group com-
parison, a statistically significant decrease in mean RMV from baseline was initially 
found at week 4 (F = 12.85; P < 0.001) in the test group. No significant decreases in 
RMVs from the baseline were seen in the control group. After 8 weeks of treatment, 
decreases in mean RMV from baseline was observed in 25 (76%) and 15 (44%) patients 
enrolled in the test and emulsion-based groups, respectively.
The significant differences in mean MASI scores between the test and the control 
groups were initially observed at weeks 4 (test, 12.7 [3.6] vs control, 16.1 [5.2]; P = 
0.005) and 8 (test, 12.4 [3.7] vs control, 15.2 [6.3]; P = 0.027) in the OT and pri-
mary ITT populations, respectively. For the within-group results with the test prod-
uct, a statistically significant decrease in MASI scores from baseline was initially ob-
served at weeks 2 (week 0, 17.7 [6.2] vs week 2, 14.0 [3.6]; P = 0.006) and 6 (week 
0, 17.3 [5.4] vs week 6, 13.6 [4.7]; P = 0.004) in the OT and primary ITT popula-
tions, respectively. No significant decreases in MASI scores from the baseline were 
observed in the control group of the OT and ITT populations.
For data from the ITT population, the inter-rater reliability (ICC) of grading the 
MASI score by each investigator ranged from 0.86 to 0.88. The Pearson correlation coef-
ficient suggested a proportional relationship between mean RMV and mean MASI scores 
of each visit (weeks 0, 2, 4, 6, and 8) and this relationship was significant (Pearson correla-
tion = 0.714; P = 0.020). 
In both ITT and OT populations, treatment with either the test or the emulsion-
based product caused a gradual increase (from week 0 to week 4) in skin pH. However, 
skin pH approached that of the baseline value after 6 weeks of treatment. Mean dif-
ferences in erythema values between the test and the control groups were not statisti-
cally significant for all measurements.
Tolerability
The AEs which occurred in patients are summarized in Table III. Overall, AEs 
were reported by 4 (12%) and 5 (15%) patients in the test and control groups, respec-
tively. The majority of AEs were burning and/or stinging. During the entire study 
period, 5 patients (7%) in the primary ITT population discontinued treatment due to 
AEs. In the test group, 2 patients (6%) experienced AEs that led to withdrawal. Three 
patients (9%) withdrew from the control group due to AEs. One patient from both groups 
reported an intense redness event. The intense redness coupled with moderate scaling was 
observed in one patient from the test group. One patient in the control group experienced 
intense erythema with edema at week 4. All patients recovered spontaneously when they 
discontinued using the products. No other serious AEs were reported.
Patient Compliance
The compliance of patients was monitored by weighing the products before and 
after the study period and checking the frequency of application of the distributed 
products during study periods. The data indicated that an average of 12.4 (0.8) g of 
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the control or 12.1 (0.6) g of the test product was used per person over 2 weeks and a 
mean of 30.2 g (0.6) of the sunscreen was used over 4 weeks. By interviewing the 
patients and assessing their diaries, it was determined that all patients followed the 
instructions of product application. They also used the sunscreen during periods of ultra- 
violet (UV) exposure and/or avoided sun exposure by wearing protective clothes or a hat.
DISCUSSION
The purpose of this study was to assess the efficacy of a formulation containing a 
combination of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl 
diglycinate/niacinamide in the treatment of melasma in Thai adults. RMV was used 
as a primary outcome for indicating the improvement of hyperpigmentation because 
this value objectively reflects the intensity of pigmentation. The primary ITT analysis 
of patients with available data showed that significant differences in mean RMV be-
tween the 2 treatment groups were observed after 6 weeks of treatment. A significant 
decrease in mean RMV from baseline was observed after 4 weeks in the test group and 
no significant reduction in RMV was noted in the control group. Similar results were 
found for the OT analysis. Additionally, in both primary ITT and OT populations, a 
higher proportion of patients in the test group showed a decrease in mean RMV from 
baseline compared with the control group. These findings indicate that the test product 
containing the combination was associated with objective reduction of melasma inten-
sity in Thai adults.
Besides mean RMV, the intensity of melasma was assessed from the visual MASI 
scored by an individual investigator. ICC in the range of 0.86 to 0.88 indicated the 
reliability of a visual scoring process. Additionally, according to the Pearson correla-
tion analysis, the proportional relationship between mean RMV and mean MASI scores 
Table III.  Adverse events (AEs) observed or reported in the test and control groups dur-
ing the study. All data are number (%).
 Test Group Control Group 
AE (n = 33) (n = 34) P*
Graded by dermatologist
  Erythema
    Slight redness 1 (3) 2 (6) 0.558
    Moderate redness 0 1 (3) 0.315
    Intense redness 1 (3) 1 (3) 0.987
  Scaling
    Dry without scaling 1 (3) 0 0.318
    Moderate scaling 1 (3) 0 0.313
  Edema 0 1 (3) 0.331
Reported by patients
  Burning and/or stinging 4 (12) 5 (15)
*2-Group t test with a 2-sided significance level of 0.05.
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of each visit indicated that the reduction of mean RMV measured using an instrumen-
tal method was aligned with the reduction of melasma intensity observed by investi-
gators. This also implies that such melasma reduction was objectively relevant and 
perceptible. However, it should be noted that there were differences between results 
from ITT and OT analysis. OT analysis suggested a significant difference in melasma 
intensity graded by visualization between the test and control groups at week 4, 
whereas ITT analysis indicated a significant difference of melasma intensity at week 8. 
Within-group analysis provided a statistically significant decrease in MASI scores 
from the baseline at weeks 2 and 6 in the OT and primary ITT populations, respec-
tively. These differences may involve exclusion of patients with large intensity and size 
of melasma, so that a substantial improvement was seen by visualization in the OT 
population with lower intensity.
In the present study, the clinical improvement of melasma in the test group might 
result from interference in different steps of the melanogenesis pathway by the active 
agents contained in the combination. TXA might suppress melanogenesis caused 
by UV light exposure by inhibition of synthesis of arachidonic acid and/or prosta- 
glandins,10,11,23 which are the mediators of melanocyte stimulation. Together with 
tyrosinase inhibitory activity of PAD12 and melanosome transfer inhibitory activity of 
niacinamide,14 the melanogenesis inhibitory activity would be enhanced. In addition, 
the synergistic beneficial effect of the combination might be enhanced by using the 
sunscreen with SPF 30 throughout the study period.
One more expectation from use of the combination is to reduce the risk of adverse 
effects. The test product was tolerated well during the study period of 8 weeks. Type 
and frequency of AEs were consistent with azelaic acid in the treatment of melasma 
as the irritant effects were mild and transient.7 A multicenter, randomized, double-
masked, parallel-group study assessed the efficacy, safety, and tolerability of azelaic 
acid 20% cream compared with those of its vehicle for the treatment of facial hyper-
pigmentation in darker-skinned patients. The mean severity scores of AEs after treat-
ment with 20% azelaic acid for 24 weeks were <1 (below trace levels).24 In the present 
study, all AEs are unlikely to be from the combination as the incidences occurred 
in both treatment groups. Moreover, the proportions of patients with AEs in the test 
(4 [12%]) and control (5 [15%]) groups were not significantly different. Skin pH of 
test or emulsion-based group gradually increased from week 0 to week 4. However, it 
was closer to the baseline value (5.1–5.3) after 6 weeks of treatment in both groups. 
In general, normal skin pH is in the acidic range (between 4.0–6.5) which acts as a 
buffer against alkaline irritants, whereas many forms of eczema cause an alkaline shift 
in the skin pH.25 Therefore, skin surface pH measurement can be used to indicate 
subclinical eczema in irritation tests and evaluation therapy.26 Besides skin pH, the 
tolerability to the products could confirm with the erythema values that did not sig-
nificantly change in all measurements in comparison with the baseline value.
A limitation of this study was the exclusion criteria that limited the ability to ex-
trapolate the results to the group of majority men, smokers, alcohol drinkers, and/or 
birth control pill users. The results from a small number of patients within this study 
may also not coincide with a larger study with a variety of population and skin types. 
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In addition, a small number of patients together with a short duration of follow-up 
(8-week study) may lead to a relative lack of power and a limited ability to detect 
potentially important differences in clinically relevant AEs. Future studies with a 
larger number of patients and longer duration should be performed to ensure the 
beneficial effects of the combination formulation for melasma treatment.
CONCLUSIONS
The significant differences in RMVs between the test and control groups were ob-
served after 6 weeks of treatment, both in the primary ITT and OT populations. The 
incidence of patients with AEs was not significantly different between the test and 
control groups. 
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